NASDAQ$KALA
Kala Bio Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2019.
Kala Pharmaceuticals reported Q4 2019 financial results, with net product revenue of $1.2 million from INVELTYS sales. The company completed the last patient visit for the STRIDE 3 trial and anticipates topline results in Q1 2020.
- Completed the last patient last visit in STRIDE 3 Phase 3 trial for EYSUVIS.
- Targeting topline results from STRIDE 3 in Q1 2020 and NDA resubmission in H1 2020.
- Reported approximately 47,000 INVELTYS prescriptions in Q4 2019, a 17% increase compared to Q3 2019.
- Kala had $85.4 million in cash as of December 31, 2019, expected to fund operations into Q2 2021.
Headline financials
Revenue & EPS history
Kala Bio · Revenue · Quarterly
$1.18M
Forward guidance
Kala anticipates existing cash resources and projected INVELTYS revenue will fund operations into the second quarter of 2021. The company is on track to report topline data in Q1 2020 and resubmit the NDA for EYSUVIS in Q2 2020.
Tailwinds
- On track to report topline data from STRIDE 3 in the first quarter of 2020.
- Targeting NDA resubmission to the FDA in the second quarter of 2020.
- Existing cash resources and projected INVELTYS revenue will fund operations into the second quarter of 2021.
- Completed the last patient last visit in STRIDE 3 Phase 3 trial for EYSUVIS.
- If approved, EYSUVIS could become the preferred prescription therapy for dry eye flares.
Headwinds
- Uncertainties inherent in the availability and timing of data from ongoing clinical trials, including STRIDE 3.
- Risk of additional clinical trials being required for EYSUVIS prior to approval of the NDA.
- Potential inability to execute on the commercial launch of EYSUVIS, if and when approved, on the timeline expected.
- Risk that the Company will be unable to generate its projected net product revenue on the timeline expected.
- Risk that the Company's cash resources will be insufficient to fund operating expenses and capital expenditure requirements for the Company's expected timeline.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2019
+1.5%
Avg return
Earnings day
+0.1%
Avg return
5 days after
-4.7%
Avg return
30 days after
40%
14 / 35 earnings
Positive
+119.7%
Q4 2022
Best reaction
-18.3%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.6% | -17.4% | -17.7% | |
| Q3 2025 | -7.4% | -10.4% | -9.7% | |
| Q2 2025 | +2.0% | +9.9% | +103.2% | |
| Q1 2025 | -5.0% | +4.6% | +23.6% | |
| Q4 2024 | -1.5% | +1.5% | +0.0% | |
| Q3 2024 | -6.1% | -9.5% | -17.7% | |
| Q2 2024 | +3.2% | -1.7% | -1.7% | |
| Q1 2024 | -0.9% | -3.9% | -12.0% | |
| Q4 2023 | +0.3% | -2.4% | -21.0% | |
| Q3 2023 | -6.6% | -2.2% | +19.7% | |
| Q2 2023 | -6.5% | -8.4% | -7.9% | |
| Q1 2023 | -2.8% | +3.0% | -5.3% | |
| Q4 2022 | +119.7% | +114.5% | +48.0% | |
| Q3 2022 | +23.7% | +34.9% | -1.9% | |
| Q2 2022 | -3.4% | -4.6% | -1.7% | |
| Q1 2022 | +8.2% | -5.4% | -43.1% | |
| Q4 2021 | -16.6% | -25.1% | -61.9% | |
| Q3 2021 | +4.3% | -7.7% | -30.4% | |
| Q2 2021 | -6.3% | -4.8% | -2.7% | |
| Q1 2021 | -18.3% | -18.4% | -9.0% | |
| Q4 2020 | -17.0% | -17.6% | -21.4% | |
| Q3 2020 | -1.8% | +0.6% | +2.5% | |
| Q2 2020 | -2.7% | -2.5% | -13.2% | |
| Q1 2020 | -2.8% | +2.8% | +17.0% | |
| Q4 2019 | +3.5% | +1.6% | +1.3% | |
| Q3 2019 | +7.0% | -4.4% | +4.2% | |
| Q2 2019 | +1.2% | -0.6% | -20.6% | |
| Q1 2019 | -8.6% | -17.2% | -24.2% | |
| Q4 2018 | +1.0% | +6.6% | -1.6% | |
| Q3 2018 | -5.4% | -13.8% | -25.9% | |
| Q2 2018 | +1.6% | -3.9% | -8.5% | |
| Q1 2018 | +2.0% | +3.7% | -16.0% | |
| Q4 2017 | -7.1% | -7.4% | -7.4% | |
| Q3 2017 | -3.6% | +2.6% | +1.7% | |
| Q2 2017 | +5.4% | +6.2% | -3.7% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro